Cargando…

The world is not enough – the value of increasing registry data in idiopathic pulmonary fibrosis

Detalles Bibliográficos
Autores principales:	Moor, C. C., Kreuter, M., Luppi, F., Wuyts, W. A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7203830/ https://www.ncbi.nlm.nih.gov/pubmed/32375778 http://dx.doi.org/10.1186/s12931-020-01377-1

Ejemplares similares

Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis
por: Costabel, Ulrich, et al.
Publicado: (2019)

Idiopathic pulmonary fibrosis mortality in the Italian epicenter of COVID-19 pandemic
por: Faverio, P., et al.
Publicado: (2023)

Increased circulating desmosine and age-dependent elastinolysis in idiopathic pulmonary fibrosis
por: de Brouwer, Bart, et al.
Publicado: (2018)

Idiopathic scrotal calcinosis: Is cytological diagnosis enough?
por: Chakrabarti, Indranil, et al.
Publicado: (2013)

Oral submucous fibrosis: Are we doing enough?
por: Chugh, Ankita, et al.
Publicado: (2019)

Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry
por: Wuyts, Wim A., et al.
Publicado: (2019)

A home monitoring program including real-time wireless home spirometry in idiopathic pulmonary fibrosis: a pilot study on experiences and barriers
por: Moor, C. C., et al.
Publicado: (2018)

Study protocol of an international patient-led registry in patients with pulmonary fibrosis using online home monitoring: I-FILE
por: Nakshbandi, Gizal, et al.
Publicado: (2023)

How many patients with idiopathic pulmonary fibrosis are there in Brazil?
por: Baddini-Martinez, José, et al.
Publicado: (2015)

Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design
por: Santermans, Eva, et al.
Publicado: (2019)

Quality of Life and Healthcare Resource Use in a Real-world Patient Population with Idiopathic Pulmonary Fibrosis: The PROOF Registry
por: Wuyts, Wim A., et al.
Publicado: (2022)

Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension
por: Richeldi, Luca, et al.
Publicado: (2018)

Changes in the respiratory microbiome during acute exacerbations of idiopathic pulmonary fibrosis
por: Molyneaux, Philip L., et al.
Publicado: (2017)

Baseline clinical characteristics, comorbidities and prescribed medication in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry
por: Wuyts, Wim A, et al.
Publicado: (2018)

There are not enough data to conclude that Monomethylsilanetriol is safe
por: Vanden Berghe, Dirk A
Publicado: (2013)

Myelodysplastic syndromes and idiopathic pulmonary fibrosis: a dangerous liaison
por: Papiris, Spyros A., et al.
Publicado: (2019)

Monocyte as a prognostic marker in patients with idiopathic pulmonary fibrosis
por: Zhu, Shiping
Publicado: (2021)

Idiopathic pulmonary fibrosis beyond the lung: understanding disease mechanisms to improve diagnosis and management
por: Luppi, Fabrizio, et al.
Publicado: (2021)

COVID-19 in a patient with idiopathic pulmonary fibrosis successfully treated with Ruxolitinib
por: Caradec, E., et al.
Publicado: (2021)

Patient Registries in Idiopathic Pulmonary Fibrosis
por: Culver, Daniel A., et al.
Publicado: (2019)

Ct value is not enough to discriminate patients harbouring infective virus
por: Romero-Gómez, María Pilar, et al.
Publicado: (2021)

Best supportive care for idiopathic pulmonary fibrosis: current gaps and future directions
por: Ferrara, Giovanni, et al.
Publicado: (2018)

Management of Acute Exacerbation of Idiopathic Pulmonary Fibrosis in Specialised and Non-specialised ILD Centres Around the World
por: Polke, Markus, et al.
Publicado: (2021)

First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value
por: Wuyts, Wim A., et al.
Publicado: (2016)

Comment on “Analysis of Microarray-Identified Genes and MicroRNAs Associated with Idiopathic Pulmonary Fibrosis”
por: Li, Chenyu, et al.
Publicado: (2018)

Coronavirus disease 2019 pneumonia may present as an acute exacerbation of idiopathic pulmonary fibrosis
por: Lee, Yong Hoon, et al.
Publicado: (2020)

Pathophysiological Studies Are Mandatory to Understand the Benefit of Proton Pump Inhibitors in Patients with Idiopathic Pulmonary Fibrosis
por: Savarino, Edoardo, et al.
Publicado: (2016)

Response to: Comment on “Analysis of Microarray-Identified Genes and MicroRNAs Associated with Idiopathic Pulmonary Fibrosis”
por: Fan, Lichao, et al.
Publicado: (2019)

Management of idiopathic pulmonary fibrosis: selected case reports
por: Kreuter, Michael, et al.
Publicado: (2014)

Collecting Occupational Exposure Data Would Strengthen Idiopathic Pulmonary Fibrosis Registries
por: Nett, Randall J., et al.
Publicado: (2020)

Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry
por: Behr, Jürgen, et al.
Publicado: (2015)

Effects of hypoxia and hyperoxia on the differential expression of VEGF-A isoforms and receptors in Idiopathic Pulmonary Fibrosis (IPF)
por: Barratt, Shaney L., et al.
Publicado: (2018)

Assessing the Effectiveness of Pirfenidone in Idiopathic Pulmonary Fibrosis: Long-Term, Real-World Data from European IPF Registry (eurIPFreg)
por: Krauss, Ekaterina, et al.
Publicado: (2020)

RESEARCH IN INDIA: NOT GOOD ENOUGH?
por: Patel, Vikram
Publicado: (2001)

Is Current Social Distancing Enough?
por: Kenjeres, Sasa, et al.
Publicado: (2021)

Integrating Patient Perspectives into Personalized Medicine in Idiopathic Pulmonary Fibrosis
por: Moor, Catharina C., et al.
Publicado: (2017)

The therapy of idiopathic pulmonary fibrosis: what is next?
por: Somogyi, Vivien, et al.
Publicado: (2019)

First and second wave of SARS-CoV2 in Italian Cystic Fibrosis patients: Data from Italian Cystic Fibrosis Registry
por: Padoan, Rita, et al.
Publicado: (2021)

PulmoCor: national registry for pulmonary hypertension
por: Post, M. C., et al.
Publicado: (2016)

Long-term survival following unilateral lung transplantation for end-stage silicosis relative to idiopathic pulmonary fibrosis
por: Perin, Fabiola Adélia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4mta732veo63fkhjust953p0do